A race for RAGE ligands.
In experimental animals a causal involvement of the multiligand receptor for advanced glycation end products (RAGE) in the development of diabetic vascular complications has been demonstrated. However, the nature of RAGE ligands present in patients with diabetic nephropathy has not yet been defined; this leaves open the relevance of the RAGE system to the human disease.
Schleicher
Erwin D
ED
Department of Medizinische Klinik und Poliklinik IV, Eberhard-Karls-Universitat, Tubingen, Germany. erwin.schleicher@med.uni-tuebingen.de
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D003925:Diabetic Angiopathies / Q000209:etiology; D003928:Diabetic Nephropathies / Q000097:blood*; D006801:Humans; D008024:Ligands; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D008970:Molecular Weight; D011485:Protein Binding; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*
D008024:Ligands; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic